PACB · NASDAQ
Pacific Biosciences of California (PACB) Stock Price & Fundamentals
Pacific Biosciences of California (PACB) closed at $452.44 on Oct 9, 2026, down 0.73% from the previous close of $455.78.
Share price, past year
1Y +10.15%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $452.44 |
| Sep 30, 2026 | $453.39 |
| Aug 31, 2026 | $451.99 |
| Jul 31, 2026 | $470.25 |
| Jun 30, 2026 | $461.34 |
| May 29, 2026 | $443.67 |
| Apr 30, 2026 | $446.63 |
| Mar 31, 2026 | $450.87 |
| Feb 27, 2026 | $440.33 |
| Jan 30, 2026 | $408.54 |
| Dec 31, 2025 | $416.81 |
| Nov 28, 2025 | $401.43 |
| Oct 31, 2025 | $394.19 |
Key statistics
- Market cap
- $140.62B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.41
- Revenue (TTM)
- $159.27M
- Net income (TTM)
- −$131.39M
- Shares outstanding
- 310.8M
- Dividend yield
- —
- 52-week range
- $388.10 – $476.09
Pacific Biosciences of California's market cap is $140.62B, based on a share price of $452.44 and 310.8M shares outstanding as of Jun 30, 2026.
Financials
Pacific Biosciences of California reported revenue of $160.01M for fiscal 2025, up 3.89% from fiscal 2024.
Pacific Biosciences of California reported a net loss of $546.38M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $160.01M | +3.9% | −$546.38M | −341.5% | −$1.82 | −$113.92M |
| FY2024ended Dec 31, 2024 | $154.01M | −23.2% | −$309.85M | −201.2% | −$1.59 | −$212.25M |
| FY2023ended Dec 31, 2023 | $200.52M | +56.3% | −$306.74M | −153.0% | −$1.21 | −$268.02M |
| FY2022ended Dec 31, 2022 | $128.30M | −1.7% | −$314.25M | −244.9% | −$1.40 | −$279.96M |
| FY2021ended Dec 31, 2021 | $130.51M | +65.4% | −$181.22M | −138.9% | −$0.89 | −$117.11M |
| FY2020ended Dec 31, 2020 | $78.89M | −13.2% | $29.40M | 37.3% | $0.17 | $18.46M |
| FY2019ended Dec 31, 2019 | $90.89M | +15.6% | −$84.13M | −92.6% | −$0.55 | −$81.15M |
| FY2018ended Dec 31, 2018 | $78.63M | −15.9% | −$102.56M | −130.4% | −$0.76 | −$68.28M |
| FY2017ended Dec 31, 2017 | $93.47M | +3.0% | −$92.19M | −98.6% | −$0.87 | −$77.95M |
| FY2016ended Dec 31, 2016 | $90.71M | — | −$74.38M | −82.0% | −$0.83 | −$76.14M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $39.01M | −$44.74M | −$0.14 |
| Q1 FY2026ended Mar 31, 2026 | $37.18M | −$8.28M | −$0.03 |
| Q4 FY2025ended Dec 31, 2025 | $44.65M | −$40.37M | −$0.11 |
| Q3 FY2025ended Sep 30, 2025 | $38.44M | −$38.00M | −$0.13 |
| Q2 FY2025ended Jun 30, 2025 | $39.77M | −$41.93M | −$0.14 |
| Q1 FY2025ended Mar 31, 2025 | $37.15M | −$426.08M | −$1.44 |
| Q4 FY2024ended Dec 31, 2024 | $39.22M | $2.37M | −$0.44 |
| Q3 FY2024ended Sep 30, 2024 | $39.97M | −$60.73M | −$0.22 |
Company profile
- Name
- Pacific Biosciences of California, Inc.
- Ticker
- PACB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Laboratory Analytical Instruments
- Headquarters
- 1305 O'Brien Drive, Menlo Park, CA 94025
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001299130
Recent SEC filings
- Aug 6, 2026
- Aug 5, 2026
- Jul 9, 2026
- Jun 4, 2026
- May 8, 2026
- May 7, 2026
- Mar 6, 2026
- Mar 5, 2026
Frequently asked questions
What is Pacific Biosciences of California's stock price?
Pacific Biosciences of California (PACB) closed at $452.44 on Oct 9, 2026, down 0.73% from the previous close of $455.78.
What is Pacific Biosciences of California's market cap?
Pacific Biosciences of California's market cap is $140.62B, based on a share price of $452.44 and 310.8M shares outstanding as of Jun 30, 2026.
How much revenue does Pacific Biosciences of California make?
Pacific Biosciences of California reported revenue of $160.01M for fiscal 2025, up 3.89% from fiscal 2024.
Does Pacific Biosciences of California pay a dividend?
Yes. Pacific Biosciences of California declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Pacific Biosciences of California, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures